Відмінності між версіями «Title Loaded From File»

Матеріал з HistoryPedia
Перейти до: навігація, пошук
м
м
Рядок 1: Рядок 1:
−
F M+F M+F Population 111 19 001 567 74 841 0.80 Age, gender, residence Population 263 9 211 three 289 119 242 1.00 Population 7 172 9 682 two.30 none Gender, year of diagnosis, age at diagnosis Hospital 12 85 five 95 2.60 Age, gender, residence Population 64 509 241 1 890 0.80 Age, gender, race Population 39 89 164 348 0.90 Age, gender, race, residence Hospital 62 91 203 210 0.70 Age, gender, race, disease status Population 4 72 7 308 two.30 Age, registration year Non-RA RA Non-RA Year Country Sex Controls Situations OR Controlled Aspects Controls Pearce NE 1986 New Zealand Cohen HJ 1987 USA Nation Finland Denmark Finland England USA USA USA USA Sweden Denmark M+F 7 159 M+F 72 309 M+F 84 475 M M+F 2 982 two 94 64 81 four M+F 7 830 19 M+F 26 623 38 M+F 9 469 eight M+F 20 699 21 M+F 46 101 28 Sex [http://www.medchemexpress.com/HG6-64-1.html HG 6-64-1 biological activity] Cohort Size Quantity of MM SIR two.20 1.10 1.20 1.66 2.00 2.36 1.17 0.90 0.88 1.76 Follow-up Duration 213 911 144 421 65 391 151 987 33 410 7 791 27 years 405 540 731 954 24 811 Boffetta P 1989 USA Lewis DR 1994 USA Vlajinac HD 2003 Yugoslavia Landgren O 2006 USA Anderson LA 2009 USA Lindqvist EK 2011 Sweden Abbreviations: RA, rheumatoid arthritis; OR, odds ratio; CI, self-confidence intervals; M, male; F, female. Excludes research by the groups of Pearce, Landgren and Brown. Excludes studies by the groups of Pearce and Landgren. Abbreviations: N, number; RR, relative threat; NS, not substantial; CI, confidence interval. doi:ten.1371/journal.pone.0091461.t003 4 Several Myeloma in Rheumatoid Arthritis I2 72.9 54.6 75.7 71.3 72.7 64.three 61.four 80.9 67.3 72.0 75.9 70.four 77.7 80.four 71.2 eight.1 69.1 59.5 62.five 45.9 77.9 47.eight 80.6 Subgroup Overall Study design Analyses Cohort Case-control RR 1.32 0.92 1.ten 1.15 1.29 0.95 1.02 1.30 1.48 1.25 1.36 1.17 1.25 1.37 1.63 1.17 0.81 1.02 1.14 0.88 0.91 1.28 0.92 1.22 p-value,0.001 0.031,0.001,0.001,0.001 0.024 0.008,0.001 0.047 0.002,0.001 0.017,0.001,0.001 0.015 0.352 0.021 0.060 0.046 0.116 0.033 0.088 0.023 Publication year Prior to 2000 Following 2000 Study good quality Regiona NOS#5 NOS.5 USA Europe Cohort Publication year Just before 2000 Immediately after 2000 Study good quality NOS#5 NOS.five Area Mean follow-upb USA Europe ,five years $5 years Case-control Publication year Just before 2000 Immediately after 2000 Study high-quality Regiona NOS#5 NOS.five USA Europe Manage variety Population Hospital Abbreviations: N, number; M, male; F, female; RR, relative danger; NOS, Newcastle-Ottawa Scale.
+
meters on Their Isolation and Stability. [http://www.ncbi.nlm.nih.gov/pubmed/ 23388095  23388095] J Mol Diagn 15: 827834. 20. Livak KJ, Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR as well as the 2) Process. Techniques 25: 402408. 21. Lewis BP, Burge CB, Bartel DP Conserved seed pairing, generally flanked by adenosines, indicates that a large number of human genes are microRNA targets. Cell 120: 1520. 22. Huang da W, Sherman [http://www.ncbi.nlm.nih.gov/pubmed/1480666 1480666] BT, RA L Systematic and integrative evaluation of substantial gene lists using DAVID bioinformatics resources. Nat Protoc four: 4457. 23. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. Bioconductor: open computer software improvement for computational biology and bioinformatics. Genome Biol 5: R80. 24. Castro MA, Wang X, Fletcher MN, Meyer KB, Markowetz F RedeR: R/ Bioconductor package for representing modular structures, nested networks and multiple levels of hierarchical associations. Genome Biol 13: R29. 25. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, et al. MicroRNA-21 contributes to myocardial illness by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980984. 26. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, et al. Expression of microRNAs is dynamically regulated for the duration of cardiomyocyte hypertrophy. J Mol Cell [http://www.medchemexpress.com/Calcipotriol.html get MC 903] Cardiol 42: 11371141. 27. Zhu H, Yang Y, Wang Y, Li J, Schiller PW, et al. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovasc Res 92: 7584. 28. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, et al. A signature pattern of stress-responsive microRNAs that may evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 103: 1825518260. 29. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial harm in cardiovascular illness. Circ Cardiovasc Genet three: 499506. 30. van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, et al. A household of microRNAs encoded by myosin genes governs myosin expression and muscle overall performance. Dev Cell 17: 662673. 31. Duan X, Ji B, Wang X, Liu J, Zheng Z, et al. Expression of MicroRNA-1 and MicroRNA-21 in Diverse Protocols of Ischemic Conditioning in an Isolated Rat Heart Model. Cardiology 122: 3643. 32. Cheng Y, Liu X, Zhang S, Lin Y, Yang J, et al. MicroRNA-21 protects against the HO-induced injury on cardiac myocytes through its target gene PDCD4. J Mol Cell Cardiol 47: 514. 33. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, et al. Stressdependent cardiac remodeling happens within the absence of microRNA-21 in mice. J Clin Invest 120: 39123916. 34. Zhang X, Azhar G, Wei JY The expression of microRNA and microRNA clusters in the aging heart. PLoS One 7: e34688. 35. Bernardo BC, Weeks KL, Pretorius L, McMullen JR Molecular distinction in between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic tactics. Pharmacol Ther 128: 191227. 36. Han M, Yang Z, Sayed D, He M, Gao S, et al. GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism in the course of cardiac hypertrophy. Cardiovasc Res 93: 645654. 37. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M MicroRNAs play an vital function within the improvement of cardiac hypertrophy.

Версія за 16:03, 27 червня 2017

meters on Their Isolation and Stability. 23388095 23388095 J Mol Diagn 15: 827834. 20. Livak KJ, Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR as well as the 2) Process. Techniques 25: 402408. 21. Lewis BP, Burge CB, Bartel DP Conserved seed pairing, generally flanked by adenosines, indicates that a large number of human genes are microRNA targets. Cell 120: 1520. 22. Huang da W, Sherman 1480666 BT, RA L Systematic and integrative evaluation of substantial gene lists using DAVID bioinformatics resources. Nat Protoc four: 4457. 23. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. Bioconductor: open computer software improvement for computational biology and bioinformatics. Genome Biol 5: R80. 24. Castro MA, Wang X, Fletcher MN, Meyer KB, Markowetz F RedeR: R/ Bioconductor package for representing modular structures, nested networks and multiple levels of hierarchical associations. Genome Biol 13: R29. 25. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, et al. MicroRNA-21 contributes to myocardial illness by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980984. 26. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, et al. Expression of microRNAs is dynamically regulated for the duration of cardiomyocyte hypertrophy. J Mol Cell get MC 903 Cardiol 42: 11371141. 27. Zhu H, Yang Y, Wang Y, Li J, Schiller PW, et al. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovasc Res 92: 7584. 28. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, et al. A signature pattern of stress-responsive microRNAs that may evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 103: 1825518260. 29. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial harm in cardiovascular illness. Circ Cardiovasc Genet three: 499506. 30. van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, et al. A household of microRNAs encoded by myosin genes governs myosin expression and muscle overall performance. Dev Cell 17: 662673. 31. Duan X, Ji B, Wang X, Liu J, Zheng Z, et al. Expression of MicroRNA-1 and MicroRNA-21 in Diverse Protocols of Ischemic Conditioning in an Isolated Rat Heart Model. Cardiology 122: 3643. 32. Cheng Y, Liu X, Zhang S, Lin Y, Yang J, et al. MicroRNA-21 protects against the HO-induced injury on cardiac myocytes through its target gene PDCD4. J Mol Cell Cardiol 47: 514. 33. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, et al. Stressdependent cardiac remodeling happens within the absence of microRNA-21 in mice. J Clin Invest 120: 39123916. 34. Zhang X, Azhar G, Wei JY The expression of microRNA and microRNA clusters in the aging heart. PLoS One 7: e34688. 35. Bernardo BC, Weeks KL, Pretorius L, McMullen JR Molecular distinction in between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic tactics. Pharmacol Ther 128: 191227. 36. Han M, Yang Z, Sayed D, He M, Gao S, et al. GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism in the course of cardiac hypertrophy. Cardiovasc Res 93: 645654. 37. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M MicroRNAs play an vital function within the improvement of cardiac hypertrophy.

Отримано з http://istoriya.soippo.edu.ua/index.php?title=Title_Loaded_From_File&oldid=194929